Advanced

Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo (R) (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess (R)/Comtan (R) (Entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment

Brooks, D J; Agid, Y; Eggert, K; Widner, Håkan LU ; Ostergaard, K and Holopainen, A (2005) In European Neurology 53(4). p.197-202
Abstract
The aim of this study was to evaluate the efficacy of the new optimised levoclopa, Stalevo(R) (levoclopa, carbidopa and entacapone) in patients with Parkinson's disease experiencing end-of-close wearing-off. Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCl) formulations along with adjunct entacapone (Comtess(R)/Comtan(R)). A European, open, parallel-group, active treatment-controlled phase IIIb study evaluating 176 patients randomised to switch from their current regimen of levodopa/DDCl to either an equivalent dose of Stalevo or levodopa/DDCl plus entacapone. After 6 weeks, treatments were assessed using the Clinical Global Impression of Change, the Unified... (More)
The aim of this study was to evaluate the efficacy of the new optimised levoclopa, Stalevo(R) (levoclopa, carbidopa and entacapone) in patients with Parkinson's disease experiencing end-of-close wearing-off. Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCl) formulations along with adjunct entacapone (Comtess(R)/Comtan(R)). A European, open, parallel-group, active treatment-controlled phase IIIb study evaluating 176 patients randomised to switch from their current regimen of levodopa/DDCl to either an equivalent dose of Stalevo or levodopa/DDCl plus entacapone. After 6 weeks, treatments were assessed using the Clinical Global Impression of Change, the Unified Parkinson's Disease Rating Scale and a Motor Fluctuations Questionnaire. Over 70% of patients in both the Stalevo, and adjunct entacapone arms felt that they were clinically improved and over 80% experienced a reduction in fluctuations. Although there was no significant difference between Stalevo and levodopa/DDCl plus entacapone with regard to motor improvement and side effects, 81% of patients stated that they preferred treatment with Stalevo compared with taking two separate tablets (i.e. levodopa/DDCl and entacapone). Stalevo was well tolerated and safe when substituted for levodopa DDCl preparations. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
wearing-off, catechol-O-methyltransferase inhibition, inhibitor, dopa-decarboxylase, levodopa, Parkinson's disease, Stalevo (R)
in
European Neurology
volume
53
issue
4
pages
197 - 202
publisher
Karger
external identifiers
  • pmid:15970632
  • wos:000231064500006
  • scopus:22744453722
ISSN
1421-9913
DOI
10.1159/000086479
language
English
LU publication?
yes
id
77fbd65f-c0bc-4dff-b5f7-a6dde98d93eb (old id 229717)
date added to LUP
2007-09-21 09:29:22
date last changed
2017-08-06 03:45:25
@article{77fbd65f-c0bc-4dff-b5f7-a6dde98d93eb,
  abstract     = {The aim of this study was to evaluate the efficacy of the new optimised levoclopa, Stalevo(R) (levoclopa, carbidopa and entacapone) in patients with Parkinson's disease experiencing end-of-close wearing-off. Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCl) formulations along with adjunct entacapone (Comtess(R)/Comtan(R)). A European, open, parallel-group, active treatment-controlled phase IIIb study evaluating 176 patients randomised to switch from their current regimen of levodopa/DDCl to either an equivalent dose of Stalevo or levodopa/DDCl plus entacapone. After 6 weeks, treatments were assessed using the Clinical Global Impression of Change, the Unified Parkinson's Disease Rating Scale and a Motor Fluctuations Questionnaire. Over 70% of patients in both the Stalevo, and adjunct entacapone arms felt that they were clinically improved and over 80% experienced a reduction in fluctuations. Although there was no significant difference between Stalevo and levodopa/DDCl plus entacapone with regard to motor improvement and side effects, 81% of patients stated that they preferred treatment with Stalevo compared with taking two separate tablets (i.e. levodopa/DDCl and entacapone). Stalevo was well tolerated and safe when substituted for levodopa DDCl preparations.},
  author       = {Brooks, D J and Agid, Y and Eggert, K and Widner, Håkan and Ostergaard, K and Holopainen, A},
  issn         = {1421-9913},
  keyword      = {wearing-off,catechol-O-methyltransferase inhibition,inhibitor,dopa-decarboxylase,levodopa,Parkinson's disease,Stalevo (R)},
  language     = {eng},
  number       = {4},
  pages        = {197--202},
  publisher    = {Karger},
  series       = {European Neurology},
  title        = {Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo (R) (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess (R)/Comtan (R) (Entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment},
  url          = {http://dx.doi.org/10.1159/000086479},
  volume       = {53},
  year         = {2005},
}